IN2014MU00651A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU00651A IN2014MU00651A IN651MU2014A IN2014MU00651A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A IN 651MU2014 A IN651MU2014 A IN 651MU2014A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN651MU2014 IN2014MU00651A (el) | 2014-02-25 | 2014-02-25 | |
| US15/121,514 US10925871B2 (en) | 2014-02-25 | 2015-02-25 | Pharmaceutical compositions of sitagliptin |
| PCT/IN2015/000104 WO2015128877A1 (en) | 2014-02-25 | 2015-02-25 | Pharmaceutical compositions of sitagliptin |
| PH12016501686A PH12016501686A1 (en) | 2014-02-25 | 2016-08-25 | Pharmaceutical compositions of sitagliptin |
| ZA2016/06075A ZA201606075B (en) | 2014-02-25 | 2016-09-01 | Pharmaceutical compositions of sitagliptin |
| US17/156,809 US20210137920A1 (en) | 2014-02-25 | 2021-01-25 | Pharmaceutical compositions of sitagliptin |
| US18/480,820 US20240024312A1 (en) | 2014-02-25 | 2023-10-04 | Pharmaceutical compositions of sitagliptin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN651MU2014 IN2014MU00651A (el) | 2014-02-25 | 2014-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU00651A true IN2014MU00651A (el) | 2015-10-23 |
Family
ID=53181316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN651MU2014 IN2014MU00651A (el) | 2014-02-25 | 2014-02-25 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10925871B2 (el) |
| IN (1) | IN2014MU00651A (el) |
| PH (1) | PH12016501686A1 (el) |
| WO (1) | WO2015128877A1 (el) |
| ZA (1) | ZA201606075B (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019087054A1 (en) * | 2017-11-01 | 2019-05-09 | Zenvision Pharma Llp | Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12 |
| WO2020018034A2 (en) | 2018-04-17 | 2020-01-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Oral pharmaceutical compositions comprising dpp-4 inhibitor |
| CN109893505B (zh) * | 2019-04-18 | 2021-06-29 | 上海海洋大学 | 由天然植物蛋白作为载体制备包含川陈皮素的固体分散体 |
| TR201910633A1 (tr) | 2019-07-17 | 2021-05-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Si̇taglipti̇n i̇çeren efervesan tablet kompozi̇syonu |
| EP4045048A4 (en) * | 2019-10-14 | 2023-05-24 | Santa Farma Ilaç Sanayi A.S. | ORAL FORMULATIONS COMPRISING SITAGLIPTIN HCI MONOHYDRATE WITH ENHANCED PHARMACEUTICAL CHARACTERISTICS |
| GR1010089B (el) * | 2020-09-15 | 2021-09-27 | Φαρματεν Α.Β.Ε.Ε. | Στερεη φαρμακοτεχνικη μορφη περιεχουσα σιταγλιπτινη και μεθοδος παρασκευης αυτης |
| CN113143929B (zh) * | 2021-04-15 | 2023-04-07 | 浙江诺得药业有限公司 | 一种西格列汀复方制剂的制备方法 |
| CN113679684B (zh) * | 2021-08-20 | 2023-06-16 | 北京鑫开元医药科技有限公司 | 磷酸西格列汀组合物、磷酸西格列汀片及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| EP1662876A4 (en) | 2003-09-02 | 2009-01-14 | Merck & Co Inc | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
| US20070021430A1 (en) | 2003-09-23 | 2007-01-25 | Chen Alex M | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
| EP1796671A4 (en) | 2004-09-15 | 2009-01-21 | Merck & Co Inc | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
| WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
| WO2007053904A1 (en) * | 2005-11-10 | 2007-05-18 | Alphapharm Pty Ltd | Process to control particle size |
| RU2461542C2 (ru) | 2006-06-27 | 2012-09-20 | Сандоз Аг | Новый способ получения соли |
| US8334385B2 (en) | 2007-11-02 | 2012-12-18 | Glenmark Generics Limited | Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof |
| CN101903390A (zh) | 2007-12-20 | 2010-12-01 | 雷迪博士实验室有限公司 | 制备西他列汀及其药学上可接受的盐的方法 |
| WO2009120746A2 (en) | 2008-03-25 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of sitagliptin phosphate |
| US20090247532A1 (en) | 2008-03-28 | 2009-10-01 | Mae De Ltd. | Crystalline polymorph of sitagliptin phosphate and its preparation |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| CA2729696A1 (en) * | 2008-07-03 | 2010-01-07 | Ratiopharm Gmbh | Crystalline salts of sitagliptin |
| WO2010012781A2 (en) | 2008-07-29 | 2010-02-04 | Medichem, S.A. | New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative |
| US8476437B2 (en) | 2008-08-27 | 2013-07-02 | Cadila Healthcare Limited | Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof |
| SI2691083T1 (sl) | 2011-03-29 | 2017-12-29 | Krka, D.D., Novo Mesto | Farmacevtski sestavek sitagliptina |
-
2014
- 2014-02-25 IN IN651MU2014 patent/IN2014MU00651A/en unknown
-
2015
- 2015-02-25 US US15/121,514 patent/US10925871B2/en active Active
- 2015-02-25 WO PCT/IN2015/000104 patent/WO2015128877A1/en active Application Filing
-
2016
- 2016-08-25 PH PH12016501686A patent/PH12016501686A1/en unknown
- 2016-09-01 ZA ZA2016/06075A patent/ZA201606075B/en unknown
-
2021
- 2021-01-25 US US17/156,809 patent/US20210137920A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015128877A1 (en) | 2015-09-03 |
| US20160367552A1 (en) | 2016-12-22 |
| US10925871B2 (en) | 2021-02-23 |
| PH12016501686A1 (en) | 2016-10-03 |
| US20210137920A1 (en) | 2021-05-13 |
| ZA201606075B (en) | 2017-08-30 |